Strategies to target angiogenesis include inhibition of the vessel-stabilizing properties of vascular pericytes. Pericyte depletion in early-stage non-hypoxic tumors suppressed nascent angiogenesis, tumor growth, and lung metastasis. In contrast, pericyte depletion in advanced-stage hypoxic tumors with pre-established vasculature resulted in enhanced intra-tumoral hypoxia, decreased tumor growth, and increased lung metastasis. Furthermore, depletion of pericytes in post-natal retinal blood vessels resulted in abnormal and leaky vasculature. Tumor transcriptome profiling and biological validation revealed that angiopoietin signaling is a key regulatory pathway associated with pericyte targeting. Indeed, pericyte targeting in established mouse tumors increased angiopoietin-2 (ANG2/Angpt2) expression. Depletion of pericytes, coupled with targeting of ANG2 signaling, restored vascular stability in multiple model systems and decreased tumor growth and metastasis. Importantly, ANGPT2 expression correlated with poor outcome in patients with breast cancer. These results emphasize the potential utility of therapeutic regimens that target pericytes and ANG2 signaling in metastatic breast cancer.
In Brief Keskin et al. report a tumor-progressionspecific role of vascular pericytes in promoting or restricting metastatic disease. Enhanced ANG2 signaling in pericyte-depleted hypoxic tumors promotes vascular defects and metastasis. Using murine models, they show the benefit of ANG2 blockade with vascular targeting therapies in suppressing metastasis.
INTRODUCTION
Angiogenesis that accompanies tumor progression provides cancer cells with a means to meet their increased demand for oxygen and nutrients and may also provide a route for cancer cell spread to distal tissues (Folkman, 2002; Zetter, 1998) . The complexity of blood vessel growth regulation in tumors may partake in offering adaptive mechanisms to promote rapid emergence of resistance mechanisms in response to anti-angiogenic therapies, thereby limiting their efficacy (Vasudev and Reynolds, 2014) . Inhibition of angiogenesis has been shown to suppress metastasis in some experimental tumors (Folkman, 2002; Kirsch et al., 2000; Mazzieri et al., 2011; O'Reilly et al., 1994 O'Reilly et al., , 1997 Weidner et al., 1991) , whereas in other studies it has been associated with enhanced intratumoral hypoxia and increased local tumor invasion and frequency of metastasis Ebos et al., 2009; Pà ez-Ribes et al., 2009) . Previously, we reported that the depletion of pericytes in established tumors impaired the neovascularization response and suppressed tumor growth, but enhanced tumor hypoxia and cancer cell spread to target organs of metastasis . While pericyte coverage in established tumor blood vessels may function as a gatekeeper of metastasis, the molecular mechanisms mediating the increased frequency of metastasis after pericyte targeting remain poorly characterized.
Pericytes are important regulators of angiogenesis and vascular stability in both developmental and pathological contexts (Armulik et al., 2005 (Armulik et al., , 2011 Bergers and Song, 2005; Hirschi and D'Amore, 1996) . These specialized perivascular mesenchymal cells are embedded in the basement membrane of blood vessels (Armulik et al., 2011; Strasser et al., 2010) and secrete pro-angiogenic factors at the onset of angiogenesis Bergers et al., 2003; Lu et al., 2007; Sennino et al., 2007; Song et al., 2005) , while also establishing quiescence of endothelial cells and stabilizing mature blood vessels (Benjamin et al., 1998; Greenberg et al., 2008; Hammes et al., 2002; Nasarre et al., 2009; Orlidge and D'Amore, 1987) . Such apparently opposed functions of pericytes are controlled by the evolving pericyte-endothelial cell crosstalk that occurs during tumor angiogenesis. Pericyte-endothelial cell signaling involves multiple pathways, including angiopoietin signaling (Armulik et al., 2005; Armulik et al., 2011) . At its core, Angiopoietin-1 (ANG1/Angpt1) and angiopoietin-2 (ANG2/Angpt2) are ligands for the endothelial receptor TIE2. ANG1 is mainly secreted by pericytes, fibroblasts, and cancer cells (Buchanan et al., 2012) and plays a key role in regulating blood vessel permeability. ANG1 also signals to enhance blood vessel stability by increasing the number of vessel-associated pericytes, i.e., pericyte coverage Fuxe et al., 2011; Gaengel et al., 2009; Thurston et al., 1999 Thurston et al., , 2000 . ANG2, which is largely produced by activated endothelial cells, antagonizes ANG1 and destabilizes blood vessels by promoting pericyte detachment and initiating endothelial cell sprouting Scharpfenecker et al., 2005; . Hypoxia increases ANG2 expression (Kelly et al., 2003; Oh et al., 1999; Rigamonti et al., 2014; Skuli et al., 2012) and ANG2 induces abnormal angiogenesis in the presence of VEGF-A Lobov et al., 2002; ). ANG2 blockade was reported recently to limit the onset of tumor resistance to VEGF-A signaling inhibition in RIP1-Tag2 pancreatic neuroendocrine tumors (Rigamonti et al., 2014) .
To gain a better understanding of pericytes and pericyteendothelial cell interactions and signaling in blood vessel formation, we performed experiments using genetic and pharmacologic targeting of pericytes at various stages of tumor and developmental (retinal) angiogenesis. In an effort to unravel the mechanisms of resistance to anti-vascular therapies, we focused on elucidating the regulatory cellular signaling pathways and functional contribution of pericytes to blood vessel formation during tumor progression.
RESULTS

Coverage and Functional Role of Pericytes Evolve during Tumor Progression
Anti-PDGFRb and NG2 antibodies have been used to label pericytes . Time-course analysis of pericyte labeling in orthotopically implanted 4T1 mouse mammary tumors showed PDGFRb + pericytes starting 4 days after injection of cancer cells (d4). PDGFRb + pericyte numbers increased as the tumor grew (d7, d13-15, d26) , and their proportion relative to NG2 + pericytes was higher in early-stage non-hypoxic (smaller) tumors when compared to late-stage hypoxic tumors (Figures 1A, 1B, and S1A Figure S1C )) significantly slowed tumor growth ( Figure 1D ). We previously reported that depletion of NG2 + pericytes in advanced-stage tumors also decreased tumor growth .
Depleting pericytes at an advanced tumor stage in NG2-TK and PDGFRb-TK mice decreased the tumor volume by 60% and 25% ( Figure 1D ), respectively, and significantly increased the lung metastatic burden ( Figure 1E ; . In contrast, pericyte depletion early during tumor growth (Figures 1F and S1B) and prior to the onset of intratumoral hypoxia ( Figure S1C ) reduced the tumor mass by 36% and 72% in NG2-TK and PDGFRb-TK mice, respectively (Figures 1F and S1D) , but significantly decreased the incidence of lung metastasis only in PDGFRb-TK mice (Figures 1G and S1E) . The difference in the lung metastatic burden noted in the early pericyte depletion setting between NG2-TK and PDGFRb-TK mice may be due to the important contribution of PDGFRb + pericytes to tumor angiogenesis at early stages of tumor growth, when NG2 + pericytes are still scarce (Figures 1A Figure 1 . Pericyte Depletion at Early and Late Stages of Tumor Progression Differentially Impacts Tumor Growth and Metastasis (E) H&E staining of lungs from WT and PDGFRb-TK mice with late PDGFRb + cell depletion and respective quantification of the percentage lung metastatic area.
WT, n = 11; PDGFRb-TK, n = 17. The metastatic nodules are encircled. High-magnification images of metastatic nodules are shown. Scale bar represents 20 mm.
(F) Tumor volume measurements over time, early PDGFRb + pericyte depletion. GCV treatment started before total tumor burden reached 100 mm 3 .
(G) H&E staining of lungs from WT and PDGFRb-TK mice with early PDGFRb + cell depletion and respective quantification of the percentage lung metastatic area.
WT, n = 12; PDGFRb-TK, n = 12. High-magnification images of metastatic nodules are shown. Scale bar represents 20 mm.
(H) Representative images of tumors immunolabeled for CD31 and visualization of perfused 2,000 kDa FITC-dextran in the indicated experimental groups and quantitation of FITC-dextran + area per vessel. WT early, n = 12; PDGFRb-TK early, n = 7; PDGFRb-TK late, n = 6. Scale bar represents 25 mm.
(I) Representative images of tumors immunolabeled for CD31 and desmin in the indicated experimental groups and quantification of the percentage of CD31 + vessels associated with desmin-labeling-positive pericytes. Solid arrowheads, vessels with desmin + pericyte coverage; empty arrowheads, vessels without desmin + pericyte coverage. WT n = 6; PDGFRb-TK early, n = 5;
PDGFRb-TK late, n = 6. Scale bar represents 25 mm. Data are represented as the mean ± SEM. In (D) and (F), two-way ANOVA with Bonferroni's multiple comparison test was used. For (C), (H), and (I), one-way ANOVA with Tukey post hoc analysis was used. Unless otherwise noted, unpaired two-tailed t test was used to determine statistical significance. *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant. See also Figure S1 . and 1B). PDGFRb + pericyte depletion did not affect metastasis in an experimental model of metastatic lung colonization after intravenous injection of 4T1 cancer cells ( Figure S1F) .
Together, the aforementioned data indicate that PDGFRb + pericytes broadly control metastasis of cancer cells at both early and late stages of tumor progression. We therefore focused subsequent studies on PDGFRb-TK mice and pharmacological targeting of PDGFRb signaling.
Pericyte Depletion in Advanced-Stage Tumors Is Associated with Compromised Blood Vessel Stability and Enhanced Intratumoral Hypoxia CD31 labeling of tumor blood vessels was significantly reduced in 4T1 tumors in both early and late pericyte depletion settings ( Figure S1G ). Intratumoral hypoxia, assayed by immunolabeling for pimonidazole adduct formation following injection of hypoxyprobe, was significantly reduced upon early depletion of pericytes ( Figure S1H ). In contrast, the smaller tumors in PDGFRb-TK mice in the late pericyte depletion setting displayed significantly enhanced intratumoral hypoxia compared to WT control tumors ( Figure S1H ). The increased intratumoral hypoxia noted in the late pericyte depletion setting was associated with an increase in vascular leakage as determined by systemic fluorescein isothiocyanate (FITC)-dextran permeability studies ( Figure 1H ). A similar degree of permeability was noted in the tumor-associated blood vessels of mice subjected to early pericyte depletion ( Figure 1H ). The blood vessels in the late depletion setting were deficient in desmin + cells, representing mature pericytes in structurally stable vessels (Chan-Ling et al., 2004; Kurz et al., 2008; Song et al., 2005; von Tell et al., 2006) , suggesting that these vessels were less stable ( Figure 1I ). The increased intratumoral hypoxia in these tumors was accompanied by enhanced epithelial-to-mesenchymal transition (EMT) in cancer cells, as determined by increased numbers of CK8 + cancer cells acquiring mesenchymal gene expression (aSMApositive), indicative of enhanced cancer cell invasiveness ( Figure S1I ).
Differential Effects of Pericyte Depletion on Early and Late Retinal Development
We utilized the retinal vasculature as a model system to further characterize the dynamic functional contributions of PDGFRb + pericytes to developmental angiogenesis ( Figure 2A ). In mouse neonatal pups, retinal blood vessels start forming after birth (P0) and extend from the center to the periphery in an organized network of branches and sprouts, providing an excellent model system to study developmental angiogenesis spatiotemporally (Stahl et al., 2010) . To determine the effect of pericyte depletion at early stages of retinal angiogenesis, GCV treatment of PDGFRb-TK or WT littermate pups was started on the day of birth (P0). Treatment was continued until P5, when the pups were euthanized and the retinas harvested. To assess the effect of pericyte depletion at a later stage of development, when the retina vasculature was partially established, GCV treatment of PDGFRb-TK or WT littermate pups was initiated at P4 and continued until P9. We noted that very few blood vessels developed in retinas when pericytes were depleted early in PDGFRb-TK pups compared to WT littermates ( Figures 2B and   S2A ). The lack of type IV collagen immunolabeling, which identifies the vascular basement membrane in the retinas, indicated that the lack of blood vessels after early PDGFRb + pericyte depletion was not due to vessel regression but rather impaired angiogenesis ( Figure S2B ). When pericyte depletion was delayed, we noted unperturbed blood vessel formation and sprouting angiogenesis, with blood vessels reaching the periphery of the retina (Figures 2C and  2D ). In this setting, isolectin B4 staining showed that, although the microvascular area was not detectably affected ( Figure 2E ), blood vessel branching was significantly reduced ( Figure 2F ). Severe vascular leakage in both the central remodeling zone and peripheral front of the expanding inner vascular plexus (shown by 70 kDa FITC-dextran perfusion) was apparent after late pericyte depletion ( Figures 2G and S2C ). The pericytedepleted blood vessels also appeared dilated, with an enlarged vessel diameter allowing increased perfusion of 2,000 kDa FITCdextran ( Figure S2D ). Together, these findings indicate differential effects of depleting pericytes during the early and late stages of retinal development.
Angiopoietin Signaling Is Differentially Modulated by Temporal Pericyte Depletion during Tumor Progression and Retinal Angiogenesis
To identify the potential molecular effectors that may be responsible for enhanced metastasis following the late PDGFRb + cell depletion (in contrast to early PDGFRb + cell depletion), we compared the gene expression profiles of tumors subjected to either early or late PDGFRb + cell depletion. Growth factor signaling pathway analyses coupled to quantitative transcript level measurements revealed that the angiopoietin signaling pathway was deregulated both in the early and late pericyte depletion setting, along with the VEGF, PDGF, and HGF signaling pathways ( Figure S3A ). While all growth factors and signaling targets evaluated by qRT-PCR showed a similar upor downregulation in both the early and late pericyte-depleted experimental groups compared to their WT controls ( Figures  S3B and S3C ), Anpgt1 and Anpgt2 were uniquely deregulated in the early versus late experimental groups (Figures 3A and 3B) . Specifically, in tumors with early pericyte depletion, Angpt1 transcript levels were elevated by 5-fold while Angpt2 transcript levels were unchanged ( Figure 3A ). In contrast, in tumors with late pericyte depletion, Angpt1 transcript levels were unchanged but Angpt2 transcript levels were elevated by 3-fold ( Figure 3B ) and ANG2 protein levels by 3-fold ( Figure 3C ). This significant deregulation in transcript and protein levels in early versus late pericyte depletion was restricted to ANG1 and ANG2 ( Figures 3A and 3B ). These results indicate a switch in ANG1/ANG2 expression along with temporal targeting of PDGFRb + pericytes in tumors. In situ hybridization (ISH) supported the transcript data; indeed, we found no difference in Angpt2 signal in the early pericyte depletion setting (versus controls), whereas there was a marked Angpt2 signal in the late pericyte depletion setting ( Figure 3D ). Angpt2 transcripts were detected primarily in foci co-localizing with collagen IV and CD31 immunolabeling, supporting a focal upregulation of Angpt2 in endothelial cells (Figures 3E and 3F) . While most blood vessels displayed high levels of Angpt2 ( Figure 3E , red arrowheads), a few blood vessels lacked Angpt2 expression ( Figure 3E , white arrowheads). Differential expression of Angpt1 and Angpt2 associated with pericyte depletion was also analyzed in the retina angiogenesis model. Late depletion of retinal pericytes (P4-P7) showed unchanged Angpt1 transcript levels, whereas Angpt2 expression was increased ( Figure 3G ). Overall, these results indicate an inversed ANG1/ANG2 expression pattern in association with temporal targeting of PDGFRb + pericytes during both tumor growth and retinal angiogenesis.
Anti-ANG2 Antibody Treatment Restores the Integrity of Pericyte-Depleted Leaky Blood Vessels and Reduces Metastasis
To determine whether the increase in lung metastasis observed in 4T1 mammary tumor-bearing PDGFRb-TK mice was due to increased ANG2 expression in tumors with late pericyte depletion, we performed rescue experiments using a murinized anti-ANG2 neutralizing antibody (Srivastava et al., 2014) . Control mice were treated with an isotype-matched immunoglobulin G (IgG) antibody. In WT mice without pericyte depletion, anti-ANG2 only moderately reduced tumor growth rate ( Figure 4A ). Pericyte depletion was initiated when tumor burden reached 500 mm 3 of volume, and this produced a significant reduction in tumor growth rate ( Figure 4A ). Although the anti-ANG2 antibody did not affect the tumor growth rate in pericyte-depleted tumors ( Figure 4A ), we observed a significant reduction in the frequency of lung metastasis ( Figures 4B and 4D ). Specifically, lung metastasis trended toward a decrease in WT mice treated with anti-ANG2, and the increased lung metastasis in PDGFRb-TK mice was abated to levels observed in WT mice treated with the anti-ANG2 antibody ( Figures 4B and 4D ). Next, we assayed the impact of anti-ANG2 treatment on vascular leakage and intratumoral hypoxia. We found that anti-ANG2 treatment in the context of PDGFRb + pericyte depletion restored the structural stability of the blood vessels, as WT early, n = 6; PDGFRb-TK early, n = 6; WT late, n = 5; PDGFRb-TK late, n = 7. Angpt2: WT early, n = 6; PDGFRb-TK early, n = 4; WT late, n = 5; PDGFRb-TK late, n = 7. The control group (WT) was arbitrarily set to 1, unpaired one-tailed t test. (C) ANG2 protein levels in tumors from WT (n = 4) and PDGFRb-TK (n = 4) mice with late pericyte depletion.
(D) Angpt2 in situ hybridization on the frozen section of 4T1 tumors from WT and PDGFRb-TK mice with either early or late pericyte depletion and quantification of Angpt2 + area/field of view. WT early, n = 6; PDGFRb-TK early, n = 4; WT late, n = 6; PDGFRb-TK late, n = 5. Scale bar represents 50 mm. One-way ANOVA was used to determine statistical significance.
(E) Angpt2 in situ hybridization followed by collagen IV immunolabeling in tumors from PDGFRb-TK mice with late pericyte depletion. Red arrowheads, Angpt2/ collagen IV double-positive vessels. White arrowheads, collagen IV positive vessels that lack Angpt2 expression. Scale bar represents 50 mm.
(F) Angpt2 in situ hybridization followed by CD31 immunolabeling in tumors from PDGFRb-TK mice (late pericyte depletion). Scale bar represents 20 mm.
(G) Transcript levels of Angpt1 and Angpt2 in retinas upon late pericyte depletion (P4-P7). Angpt1: WT, n = 4; PDGFRb-TK, n = 7. Angpt2: WT, n = 4; PDGFRb-TK, n = 7. The control group was arbitrarily set to 1, unpaired one-tailed t test. Data are represented as the mean ± SEM. Unless otherwise indicated, unpaired two-tailed t test was used to determine statistical significance. *p < 0.05, **p < 0.01. ns, not significant. See also Figure S3 and Figures 4I-4J ). Tumor lymphangiogenesis (mostly peri-tumoral in this model) assayed by LYVE-1 staining was unchanged in all experimental groups ( Figure S4F ). Pericyte depletion, with and without anti-ANG2 treatment, did not impact vascular TIE2 expression ( Figure S4G ), nor tumor infiltration by TIE2-expressing macrophages ( Figure S4H ), suggesting that ANG2 upregulation in pericyte-depleted tumors acts in an autocrine manner to destabilize endothelial cells, and that the effect of anti-ANG2 treatment is mediated by suppression of the imbalanced ANG2/TIE2 signaling without affecting TIE2 expression in endothelial cells or macrophages. Finally, global gene expression profiling of the WT, PDGFRb-TK, and PDGFRb-TK tumors treated with the anti-ANG2 antibody revealed impaired angiopoietin signaling in pericyte-depleted tumors, and a gene expression pattern partially reverted to that of WT control mice after treatment with the anti-ANG2 antibody ( Figure 4K ). Then, we analyzed ANG2 signaling induced by late PDGFRb + cell depletion during retinal angiogenesis. Similar to the findings in tumors, anti-ANG2 rescued the vascular phenotype observed in the retina of PDGFRb-TK pups. The enhanced vascular leakage at the central zone of the vascular plexus and at the sprouting edge of the primary plexus was observed specifically in PDGFRb-TK mice in the late-stage pericyte depletion setting; anti-ANG2 antibody treatment re-established the retinal vessel structural stability in PDGFRb-TK mice ( Figures 5A and 5B). Enhanced vessel diameter in PDGFRb-TK mice ( Figure S3D ) was also restored by anti-ANG2 ( Figure 5C ). Anti-ANG2 treatment did not modify NG2 + pericyte coverage in retinal blood vessels ( Figures 5A and 5D ). Taken together, these results indicate that PDGFRb + pericyte depletion promotes an ANG2-mediated increase in vascular destabilization and permeability, both in tumors and the developing retinal vasculature.
Treatment of Established Breast Tumors with Imatinib and Anti-ANG2 Antibody Restores Blood Vessel Structural Stability and Limits Metastasis
We previously reported that imatinib significantly reduced pericyte coverage in 4T1 tumors . In larger tumors (tumor burden 500 mm 3 ), imatinib treatment mirrored the phenotype observed in PDGFRb-TK and NG2-TK mice, which resulted in increased vascular leakage and intratumoral hypoxia associated with lung-enhanced metastasis . To determine whether imatinib and ANG2 neutralization may synergistically decrease primary tumor burden and lung metastasis, we treated 4T1 tumor-bearing mice with a single agent (imatinib) or a combination therapy (imatinib and anti-ANG2). Control mice were treated with saline (PBS) and control IgG.
Single therapy with imatinib reduced primary tumor growth compared to control mice ( Figure 6A ), as previously reported . Combination therapy with imatinib and anti-ANG2 antibody further increased inhibition of primary tumor growth when compared to imatinib monotherapy ( Figure 6A ). Imatinib treatment in established 4T1 tumors resulted in an increase in lung metastasis (Figures 6B and 6C; ; however, the combination therapy resulted in a significant reduction of lung metastasis when compared to imatinib only ( Figures 6B and 6C ). Tumor necrosis was increased by anti-ANG2 ( Figure 6D ), as previously reported , and may contribute to the stalled tumor growth ( Figure 6A ).
Histological findings in the heart, bowel, kidney, and pancreas were unremarkable in control, imatinib alone, and imatinib/anti-ANG2 combination therapy ( Figure S5A ). A liver metastasis was noted in one of the mice treated with imatinib (in agreement with enhanced metastatic disease after imatinib monotherapy), and enlarged spleen with follicular expansion characteristic of tumor bearing mice was observed in all mice ( Figure S5A ).
Intratumoral hypoxia and vascular leakage were enhanced in tumors treated with imatinib (Figures 6E and 6F ; . Concomitant anti-ANG2 and imatinib treatment reduced intratumoral hypoxia ( Figure 6E ), vascular leakage ( Figure 6F ), and vessel diameter ( Figures S4A and S4C ). Additional targets of imatinib, such as c-Kit and Abl1, were unchanged in imatinib-treated mice ( Figure S5B ; . Collectively, these results indicate that the anti-metastatic effects of ANG2 blockade may be due, at least in part, to improved vascular stabilization and decreased tumor hypoxia. we evaluated the differential expression of the mature pericyte marker desmin (Des). Gene expression profiling showed a sustained decrease in Pdgfrb transcript levels in tumors with PDGFRb-TK mice despite anti-ANG2 antibody treatment (Figure 7A ). ANG2 blockade limited the decrease in Des transcript levels observed in tumors of PDGFRb-TK compared to control mice ( Figure 7A ). Desmin immunolabeling in proximity to CD31 vascular labeling indicated a significant increase in desmin + mature pericyte coverage of tumor vessels in PDGFRb + pericyte-depleted tumors treated with the anti-ANG2 antibody ( Figure 7B ). ANG2 blockade also promoted desmin + pericyte coverage of tumor vessels in WT mice without PDGFRb + pericyte depletion ( Figure 7B ). These results show that anti-ANG2 treatment upregulated the expression of desmin and increased vascular coverage by mature pericytes, in spite of the loss of Pdgfrb expression caused by genetic targeting of PDGFRb + pericytes.
Normalization of Angiopoietin Signaling in PDGFRb
Global gene expression signaling revealed partially restored VEGF family-ligand-receptor interactions and CXCR4 signaling pathways after anti-ANG2 treatment ( Figure 7C ). Transcriptome analyses showed that expression of Cxcr4 was increased in tumors from PDGFRb-TK compared to WT control mice (both treated with control IgG); these results were validated by qRT-PCR ( Figure 7D ). Cxcr4 expression in tumors from PDGFRb-TK mice treated with anti-ANG2 antibody was restored to levels observed in WT tumors ( Figure 7D ). These results suggest a rescued vessel permeability defect following anti-ANG2 antibody treatment. Angpt2 transcript levels were elevated in (legend continued on next page)
PDGFRb-TK tumors, corroborating our earlier observation (Figures 3A-3C ). Anti-ANG2 treatment did not suppress the transcription of Angpt2, consistent with previous findings (Mazzieri et al., 2011; Rigamonti et al., 2014) , indicating that the therapeutic effect of antibody-mediated ANG2 blockade is mediated through downstream signaling rather than via transcriptional feedback downregulation of Angpt2 ( Figure 7D ). These transcriptomic analyses support the notion that increased Angpt2 expression in tumors with late pericyte depletion may compromise vessel integrity via deregulation of CXCR4/CXCL12 signaling. Several studies have shown that CXCR4/CXCL12 plays a role in vascular permeability (Suri et al., 1998) , endothelial cell patterning and morphology (Strasser et al., 2010) , and transendothelial migration and metastasis of breast cancer cells (Lee et al., 2004; Mukherjee and Zhao, 2013; Mü ller et al., 2001 ). We also observed restored ZO-1 expression (a marker for endothelial tight junction) in endothelial cells of tumors from PDGFRb-TK mice treated with the anti-ANG2 antibody, similar to levels of control tumors (WT mice treated with IgG control) ( Figure 7E ).
ANGPT2 and PDGFRB Expression Correlate with Poor Outcome in Patients with Breast Cancer
We queried the Kaplan-Meier plotter data set and evaluated the survival probability of patients with breast cancer based on their tumor transcriptomes ( Figures  7F-7H) . The median transcript level of ANGPT1, ANGPT2, and PDGFRB was used to stratify 3,455 patient tumor transcriptomes into high and low expression for each gene. High ANGPT1 expression was associated with improved outcome ( Figure 7F ). In contrast, a significant association of high ANGPT2 expression and poor recurrence free survival was found ( Figure 7G ). In addition, low PDGFRB expression was associated with poor recurrence free survival ( Figure 7H ). These analyses are in agreement with results obtained in our mouse studies: whereas high ANGPT1 was associated with suppressed metastasis, high ANGPT2 was associated with enhanced metastasis in mice . These results are also consistent with the higher metastatic tumor burden noted in PDGFRb-TK mice (low PDGFRB), in which high ANGPT2 expression was noted ( Figures 3B-3D ).
DISCUSSION
Anti-angiogenic cancer therapies show efficacy but did not realize the full potential that preclinical studies had suggested, highlighting an unforeseen complexity of tumor neo-angiogenesis (Bisacchi et al., 2003; Folkman, 1972) . Newly formed blood vessels, or lack thereof, affect the metabolic status of the primary tumor and may influence cancer cells' metastatic potential in addition to providing routes to metastasis Folkman, 2002; Zetter, 1998 In contrast with the early pericyte depletion experiments, the late depletion of pericytes in established primary tumors resulted in a moderate decrease of tumor growth but was associated with a significant increase of lung metastasis. The late pericytedepleted tumors displayed an overall reduction of tumor blood vessels, with the remaining blood vessels characterized by hyperpermeability and poor desmin + pericyte coverage, both likely contributing to the increased intratumoral hypoxia and metastatic dissemination. The stage-specific metastasis phenotypes may also underscore the relative contribution of specific pericyte subtypes to tumor angiogenesis. Our studies on early tumor development indeed showed a differential timing for PDGFRb + and NG2 + pericytes accumulation, with increasing overlap of expression, suggesting that PDGFRb + cells acquire NG2 expression. These findings may explain, at least in part, the differences observed in early ablation of PDGFRb + versus NG2 + cells in 4T1 tumors, whereby early ablation of NG2 + cells has minimal effects on tumor growth and metastasis.
Our transcriptomic studies identified angiopoietin signaling as uniquely deregulated with respect to early versus late pericyte targeting, and we further implicated ANG2 expression and signaling as a key mediator of the metastatic phenotype associated with tumor-stage-specific PDGFRb + pericyte depletion. Using genetic depletion of PDGFRb + pericytes or (E and F) Immunolabeling for CD31 and FITC for visualization of 2,000 kDa FITC-dextran in the indicated experimental groups and quantification of the FITC + area per field of view. IgG + PDGFRb-TK, n = 3; anti-ANG2 + PDGFRb-TK, n = 3. Scale bar represents 50 mm. Unpaired two-tailed t test was used.
(G and H) Representative images of tumors immunolabeled for CK8 and aSMA in the indicated experimental groups and quantification of the relative CK8 + aSMA + cells per visual field. WT, n = 3; PDGFRb-TK, n = 3; anti-ANG2+PDGFRb-TK, n = 3. Scale bar represents 10 mm.
(I and J) Immunolabeling of hypoxyprobe (pimonidazole adduct formation) in the indicated experimental groups and quantitation of relative percentage hypoxic area. IgG + WT, n = 3; anti-ANG2 + WT, n = 3; IgG + PDGFRb-TK, n = 4; anti-ANG2 + PDGFRb-TK, n = 3. Scale bar represents 500 mm.
(K) Heatmap of the differentially regulated genes in the angiopoietin signaling pathways in the tumors of indicated experimental groups. Data are represented as the mean ± SEM. Unless otherwise noted, one-way ANOVA with Tukey post hoc analysis was used to determine statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S4 .
pharmacological targeting of PDGFRb signaling by imatinib, we showed that the leaky vascular phenotype in these tumors was associated with elevated ANG2 expression. Vessels with increased ANG2 stimulation in the Rip1Tag2 transgenic mouse model were previously characterized by reduced pericyte coverage and were found dilated, destabilized, and highly permeable (Fagiani et al., 2011) , all of which are consistent with our observations. Furthermore, our analyses also highlighted a deregulation of CXCR4/CXCL12 signaling in association with late PDGFRb + pericytes depletion, also in concordance (legend continued on next page) with its known implication in vessel permeability (Suri et al., 1998) and breast cancer cell transendothelial migration and metastasis (Lee et al., 2004; Mukherjee and Zhao, 2013; Mü ller et al., 2001 ). Our previous studies have shown that pericyte targeting in established tumors leads to increased EMT associated with increased c-MET expression in hypoxic cancer cells . The current study suggests that such increase in c-MET expression in cancer cells could be facilitated by enhanced hypoxia resulting from ANG2-mediated vascular defects.
Our results indicate ANG2-mediated destabilization of sprouting blood vessels in the hypoxic environment of the late pericyte depletion setting, and high levels of Angpt2 in this setting may be restricted to endothelial cells in the more hypoxic regions of the tumor. ANG2 has been associated with metastasis in melanoma patients; indeed, increased circulating ANG2 levels were associated with tumor progression and metastasis . The association of ANG1 with metastasis has been uncertain in clinical contexts (Szarvas et al., 2008) . Our results indicate that ANG1 expression is associated with decreased metastasis and increased desmin + pericyte coverage, and high ANGPT1 is associated with increased survival probability in surveyed breast cancer transcriptomes.
While overexpression of ANG2 increases metastasis through enhanced vascular permeability (Holopainen et al., 2012) , blocking of ANG2 signaling enhances pericyte coverage of blood vessels (Rigamonti et al., 2014) and strongly inhibits metastasis (Mazzieri et al., 2011) , possibly by stabilizing the tumor-associated vasculature via enhanced endothelial cell-cell junctions (Holopainen et al., 2012) and by displacing macrophages that assist cancer cell intravasation from the tumor blood vessels (Mazzieri et al., 2011) . Of note, anti-ANG2 suppresses both spontaneous metastasis of primary mammary tumors and the metastatic colonization of the lung after cancer cell seeding (Mazzieri et al., 2011) . In this regard, anti-ANG2 antibody treatment was recently shown to suppress metastatic growth also in the adjuvant (post-surgical) setting in mice, an effect mediated via suppression of the endothelial cell proinflammatory phenotype at the metastatic site (Srivastava et al., 2014) . While such anti-metastatic mechanism could also be at play in our studies, we also show that ANG2 blockade concomitant to PDGFRb + pericyte depletion during the late phases of tumor progression provides benefit by reducing both primary tumor growth and metastatic disease. Anti-ANG2 treatment rescued the vascular defects induced by pericyte targeting, and imatinib and anti-ANG2 combination therapy suppressed primary tumor growth and controlled lung metastasis. The vascular defects associated with pericyte targeting in retinal angiogenesis were also restored upon anti-ANG2 therapy. ANG2 signaling inhibition enhanced endothelial cell-cell tight junctions, and these results altogether suggest that ANG2 signaling is central to the loss of vascular stability associated with PDGFRb + pericyte targeting in both tumor and developmental angiogenesis. Finally, the analysis of the tumor transcriptomes of patients with breast cancer revealed a robust correlation between recurrence-free survival and expression of ANGPT2 and PDGFRB.
Our results indicate that the enhanced cancer cell dissemination induced by targeting PDGFRb + pericytes in advanced stage tumors could be controlled by the administration of an anti-ANG2 antibody. Increased intratumoral hypoxia in late-stage tumors enhances ANG2 production by endothelial cells (Holash et al., 1999; Saharinen et al., 2011) , further destabilizing the tumor vasculature and fueling a vicious cycle set forth by PDGFRb + pericyte targeting. While the anti-metastatic effects of the anti-ANG2 antibody may also be due to impaired angiogenesis and cancer cell growth at the metastatic site, our results indicate that its effects are also targeted to the primary tumors and their metastatic potential. Our findings further imply that vascular normalization and consequently improved vascular perfusion Jain, 2011a, 2011b; Jain, 2005; Li et al., 2007; Skuli et al., 2009 ) may be achieved by PGDFRb + pericyte targeting concomitant with anti-ANG2 antibody therapy. This strategy, if combined with chemotherapy, may potently suppress tumor growth by enhancing chemotherapeutic delivery while preserving the structural stability of the tumor blood vessels, thus minimizing hypoxia-induced metastatic dissemination.
EXPERIMENTAL PROCEDURES
Cells and Mice 4T1 Balb/c mammary tumor epithelial cells were obtained from ATCC and grown in DMEM media supplemented with 10% fetal bovine serum (FBS). PDGFRb-TK and NG2-TK Balb/c mice were previously described . Female mice, between the ages of 6 and 12 weeks, were used for orthotopic implantation of 4T1 mammary epithelial cancer cells, as described previously . Mice received daily intraperitoneal (i.p.) GCV injections at a 50 mg/kg body weight (BW) dose at the indicated time points and, when indicated, also received i.p. injections of a neutralizing anti-ANG2 antibody (murinized LC06, Roche Diagnostics) (Srivastava et al., 2014) or control isotype-matched IgG antibody once a week (10 mg/kg BW in 0.2 ml PBS), or imatinib or PBS by oral gavage daily (50 mg/kg BW in 0.1 ml). All mouse experiments were reviewed and approved by the Institute of Animal Care and Use Committee at the Beth Israel Deaconess Medical Center (BIDMC) and the MD Anderson Cancer Center (MDACC). Additional experimental details are listed in the Supplemental Experimental Procedures.
Tumor Vessel Leakage and Metastatic Burden
Mice were injected in the retro-orbital venous plexus with 100 ml of 10 mg/ml FITC-dextran (2,000,000 MW, Sigma) 5 min prior euthanasia. Tumor sections from optimum cutting temperature (OCT)-embedded tumors were immunostained for CD31. FITC-dextran was visualized either directly by (D) qRT-PCR for Angpt2 and Cxcr4 in tumors from the indicated experimental groups. Angpt2: IgG + WT, n = 4; IgG + PDGFRb-TK, n = 5; anti-ANG2 + PDGFRb-TK, n = 5. Cxcr4: IgG + WT, n = 4; IgG + PDGFRb-TK, n = 4; anti-ANG2 + PDGFRb-TK, n = 4. (E) Representative images of tumors immunolabeled for CD31 and ZO-1 in the indicated experimental groups and quantification of the percentage of the number of ZO-1 + vessels. IgG + WT, n = 3; IgG + PDGFRb-TK, n = 3; anti-ANG2 + PDGFRb-TK, n = 3. Scale bar represents 25 mm.
(F-H) Kaplan-Meier plots depicting the recurrence free survival probability of patients with breast cancer (n = 3,455) based on Angpt1 (F), Angpt2 (G), and Pdgfrb (H) tumor expression. HR, hazard ratio. Log-rank test was used. Data are represented as the mean ± SEM. Unless otherwise noted, one-way ANOVA with Tukey post hoc analysis was used to determine statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
fluorescent microscopy under the green fluorescent filter or by immunostaining with anti-FITC antibody and a FITC-conjugated secondary antibody. FITC-dextran is quantified by ImageJ area fraction analysis. Multiple sections/tumor were analyzed at original magnification 340 with n R 3 tumors/group. Histological assessment and quantitation of the metastatic and tumor necrosis areas are described in the Supplemental Experimental Procedures.
Microarray Analysis and qPCR Analyses
Microarray analysis was performed using Mouse Ref8 or Ref6 Gene Expression BeadChip (Illumina). Details for microarray samples, qRT-PCR analyses, and primer sequence information are listed in the Supplemental Experimental Procedures and Table S1 .
Statistical Analysis
For comparison between two groups with one grouping variable, the unpaired two-tailed Student's t test was used. For RT-PCR analyses, the unpaired onetailed Student's t test was used to compare dCt between experimental groups. To compare multiple groups, analysis of variance (ANOVA) was used with Prism software. For multiple groups with one grouping variable, one-way ANOVA with multiple comparisons with Tukey correction was performed, and, for multiple groups with two grouping variables, two-way ANOVA with Bonferroni's multiple comparison test was used. p < 0.05 was considered statistically significant. All data are represented as the mean with error bars corresponding to SEM.
ACCESSION NUMBERS
The NCBI GEO accession number for the gene expression data reported in this paper is GSE55785. Different images for this experiment are also shown in Figure 4G . Data are represented as the mean +/-SEM. Unless otherwise noted, unpaired two-tailed t-test was used to determine statistical significance. * p<0.05, ** p<0.01. ns: not significant. A Immunolabeling for NG2 (pericytes marker) and Isolectin B4 staining in retina of WT and PDGFRβ-TK mice treated with GCV from P0 to P5 (early depletion) or from P4 to P9 (late depletion). Scale bar: 500 µm. B Immunolabeling for Collagen IV followed by Isolectin B4 staining of retinas from PDGFRβ-TK mice treated with GCV from P0 to P5. Scale bar: 100 µm.
SUPPLEMENTAL INFORMATION
Supplemental Information includes
C Isolectin B4 staining and visualization of 70 kDa FITC-dextran in retina of WT and PDGFRβ-TK mice treated with GCV from P4 to P9 and quantitation of FITC-dextran + area per vessel.
Scale bar: 100 µm. WT, n=3; PDGFRβ-TK, n=5. These data are also shown in Figure 2G . D Isolectin B4 staining and visualization of 2,000 kDa FITC-dextran in retina of WT and PDGFRβ-TK mice treated with GCV from P4 to P9 and quantitation of FITC-dextran + vessel.
Scale bar: 100 µm. WT, n=3; PDGFRβ-TK, n=3. Data are represented as the mean +/-SEM.
Unpaired two-tailed t-test was used to determine statistical significance. * p<0.05. Table S1 . Primer sequences used in this study, related to Figure 3 .
Supplemental Experimental Procedures
4T1 orthotopic and intravenous mammary cancer model and agent administration
PDGFRβ-TK or littermate control female mice, between the ages of 6 and 12 weeks, were used for orthotopic implantation of 4T1 mammary epithelial cancer cells (0.5 x 10 6 in each breast pad). Data from a subset of the PDGFRβ-TK mice in the late pericyte depletion experiments shown in Figure 1 was reported in our previous studies . Ganciclovir (GCV, Invivogen) treatments were initiated once the average tumor burden reached 500 mm 3 for the late depletion group and before the average total tumor burden reached 100 mm 3 for the early depletion group. Mice received daily intraperitoneal (i.p.) GCV injections at a 50 mg/kg body weight (BW) dose. Tumor volumes were measured every 2-3 days using Vernier calipers and volumes were calculated using the formula (length x width 2 x π/6). Mice were euthanized when the tumor size of control mice reached approximately 2,500 mm 3 . Mice also received i.p.
injections of the neutralizing anti-ANG2 antibody (LC06, Roche Diagnostics) or control isotype matched IgG antibody once a week (10 mg/kg BW in 0.2 ml PBS) , or imatinib or PBS by oral gavage daily (50 mg/kg BW in 0.1 ml). For intravenous injection, 0.5 x 10 6 4T1 cells were injected in the retro-orbital venous plexus and mice euthanized 7 days post cancer cell injection. In this setting, GCV injections were initiated 3 days before cancer cell injection. Mice were also injected i.p. with a single dose of hypoxyprobe (60 mg/kg BW in 0.5 ml of pimonidazole, HPI Inc.) 30 minutes before euthanasia.
Newborn mice treatment for retina experiments
PDGFRβ-TK or littermate control newborn mice were treated with GCV dissolved in PBS from P0 to P5 (early treatment) or P4 to P9 (late treatment). Ganciclovir (50 mg/kg BW in 10 µl) was administered by i.p. injection daily for 5 consecutive days. Under anesthesia, 100 µl of 10mg/ml FITC-dextran (2,000 kDa or 70 kDa, Sigma) was injected intracardially and allowed to circulate for 5 minutes. The pups were euthanized by decapitation and the retinas as well as other organs were collected for further analysis. PDGFRβ-TK pups were also treated with anti-ANG2 or control anti-IgG antibodies in combination with GCV. Anti-ANG2 or anti-IgG was administered intraperitoneally once at P4 (10 mg/kg BW, at a volume of 10 µl) and GCV (50 mg/kg, at a volume of 10 µl) was administered daily by intraperitoneal injection until sacrifice (P9).
Quantification of metastatic burden and tumor necrosis
Hematoxylin and eosin staining of lung sections from paraffin-embedded tissue was generated by the BIDMC and MDACC histology core facilities. Image of an entire lobe of the lung was 
In situ hybridization
In situ hybridization (ISH) was performed on frozen 4T1 tumor sections using standard methods.
Briefly, frozen tumor sections (4-6 tumors/group) were cut into 10 µm-thick sections using a cryostat (Leica), post-fixed in 4% PFA, acetylated in 1% triethanolamine and 0.25% acetic anhydride, pre-hybridized, then hybridized with ANG2 probe overnight at 65°C. After hybridization, sections were washed and incubated with AP-conjugated sheep anti-DIG antibody equipped with a Nikon DS-2 digital camera or by confocal laser-scanning microscopy using a Zeiss LSM 510 META. Images were processed using Adobe Photoshop and ImageJ software.
Analysis of postnatal retinal angiogenesis
Images of whole mount retinas were taken at 10x magnification to measure vessel density. The number of branch points per field (100 X 100 µm fields, images taken with 10X magnification, 3
fields/retina and 3-4 retinas/group) at the periphery of vasculature was quantified using Image J.
FITC-dextran was visualized directly by fluorescent microscopy under the green fluorescent filter and quantified by ImageJ area fraction analysis. 3-8 fields/retina and 3-4 retinas / group were analyzed at original magnification x10. Vessel diameter was measured at original magnification x63 and 8-10 fields/ retina and 3-4 retinas / group was analyzed.
ELISA
Tumors were lysed in 300-600 µl of PBS supplemented with proteinase inhibitors (Roche) on ice. The lysate was then subjected to 2 freeze-thaw cycles then spun for 15 min at 5000 rpm at 4°C. The lysate was cleared with a second centrifugation for 15 min at 10,000 rpm at 4°C. The protein lysate was quantified using the BCA protein assay reagents (Pierce), accordingly to manufacturer's directions. 50 µg of lysates was diluted in the sample diluent buffer provided in the Angiopoietin-2 Mouse ELISA Kit (Abcam) and the ELISA was then carried out following the manufacturer's directions.
